Compare Novartis AG (NVS) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Ryanair Holdings plc — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Ryanair Holdings plc trades at $53.7 (market cap $27.11B). The key difference: Novartis AG is far larger — about 9.9× Ryanair Holdings plc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Ryanair Holdings plc for 72 Days on average.
| NVS | RYAAY | |
|---|---|---|
Market Cap | $268.57B | $27.11B |
Volume | 1,532,573 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $168.62 | $73.82 |
52-Week Low | $121.80 | $51.95 |
Typical Hold Time | 82 Days | 72 Days |
Enterprise Value | $309.89B | $24.18B |
Dividend Yield | 3.31% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
RYAAY trades at $56.00, up 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported $13.95B revenue and $1.61B net income for 2025, with valuation ratios appearing attractive (P/E 13.43, EV/EBITDA 6.05). Recent news highlights CEO commentary on Boeing MAX 10 delays and fuel cost concerns, while analyst consensus remains positive with 65% buy ratings.
RYAAY presents a value opportunity with solid profitability metrics (ROE 22.41%, net margin 12.13%) but faces near-term headwinds from oil price volatility and operational challenges. The stock's current bearish technical positioning contrasts with fundamental strength, creating potential for recovery if fuel costs stabilize and traffic targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
